XmAb-2513

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameXmAb-2513
Drug Alias NameXmAb-2513
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, Large-Cell, AnaplasticHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesXencor Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Large-Cell, AnaplasticHodgkin Disease

Other Information

ATC CodeN/A
Related LinksN/A